Study shows dietary supplements can prevent hereditary cancer – Technology Networks | Region & Cash

A study of people with a high hereditary risk of a variety of cancers has shown a great preventive effect of resistant starch contained in a variety of foods such as oatmeal, breakfast cereals, cooked and chilled pasta or rice, peas, beans, etc. easily green bananas.

An international study — known as CAPP2 — involving nearly 1,000 Lynch syndrome patients from around the world showed that regular intake of resistant starch, also known as fermentable fiber, for an average of two years did not affect colon cancer but cancer in others Parts of the body reduced by more than half. This effect was particularly pronounced in cancers of the upper gastrointestinal tract, including esophageal, gastric, bile duct, pancreatic and duodenal cancer.

The amazing effect lasted 10 years after stopping taking the supplement.

The study, led by experts from the Universities of Newcastle and Leeds, was published in today cancer prevention researcha journal of the American Association for Cancer Research, is a planned double-blind 10-year follow-up supplemented with comprehensive national cancer registry data for up to 20 years in 369 of the participants.

Previous research published as part of the same study showed that aspirin reduced colon cancer by 50%.

“We have found that resistant starch reduces a range of cancers by over 60%. The effect was most pronounced in the upper part of the gut,” explained Professor John Mathers, Professor of Human Nutrition at Newcastle University. “This is important because cancers of the upper gastrointestinal tract are difficult to diagnose and often go undetected early.

“Resistant starches can be taken as a powder supplement and occur naturally in peas, beans, oats and other starchy foods. The dose used in the study corresponds to the consumption of a daily banana; Before they become too ripe and soft, the starch in bananas resists breakdown and makes its way into the gut, where it can change the type of bacteria that live there.

“Resistant starch is a type of carbohydrate that isn’t digested in your small intestine, but instead ferments in your large intestine and feeds beneficial gut bacteria – it acts like fiber in your digestive system. This type of starch has several health benefits and fewer calories than regular starch. We believe that resistant starches can reduce cancer development by altering the bacterial metabolism of bile acids and reducing the types of bile acids that can damage our DNA and eventually cause cancer. However, this requires further research.”

Professor Sir John Burn of Newcastle University and the Newcastle Hospitals NHS Foundation Trust, who conducted the study with Professor Mathers, said: “When we started the studies over 20 years ago, we thought that people with a genetic predisposition to colon cancer were us could help to test whether we could reduce the risk of cancer with aspirin or resistant starch.

“Patients with Lynch syndrome are at high risk because they are more likely to develop cancer. Therefore, the finding that aspirin can halve the risk of colon cancer and other starch-resistant cancers is crucial.

“Based on our attempt to PRETTY (The National Institute for Health and Care Excellence) are now recommending aspirin for people at high genetic risk for cancer, the benefits are obvious – aspirin and resistant starches work.”

long-term study

Between 1999 and 2005, nearly 1,000 participants began taking either powdered resistant starch or aspirin or a placebo daily for two years.

At the end of the treatment period, there was no overall difference between those who had taken resistant starch or aspirin and those who had not. However, the research team expected a longer-term effect and designed the study for further follow-up.

During the follow-up period, only 5 new cases of upper gastrointestinal cancer occurred among the 463 participants who took the resistant starch, compared with 21 among the 455 who took the placebo.

The team is now leading the international CaPP3 study, involving more than 1,800 people with Lynch syndrome, to investigate whether smaller, safer doses of aspirin can be used to reduce the risk of cancer.

Relation: Mathers JC, Elliott F, Macrae F, et al. Cancer prevention with resistant starch in Lynch syndrome patients in the randomized placebo-controlled CAPP2 study: planned 10-year follow-up. cancer prevention research. 2022:OF1-OF12. doi: 10.1158/1940-6207.CAPR-22-0044

This article was republished from the following materials. Note: The material may have been edited for length and content. For more information, please refer to the given source.

Leave a Comment